Bayer’s restructuring hits pharma leadership, shifting about half of execs off top team

Bay­er is “ba­si­cal­ly halv­ing” the size of its phar­ma­ceu­ti­cal lead­er­ship team, a spokesper­son told End­points News, as the com­pa­ny be­gins to roll out a re­struc­tur­ing plan aimed at mak­ing it more ef­fi­cient.

The Ger­man drug­mak­er is elim­i­nat­ing six seats on the phar­ma­ceu­ti­cal di­vi­sion’s lead­er­ship team, though on­ly one ex­ec­u­tive is leav­ing the com­pa­ny, the spokesper­son said Wednes­day. The cur­rent lead­er­ship team is made up of 14 ex­ec­u­tives, in­clud­ing lead­ers from com­mu­ni­ca­tions, le­gal and HR who are not af­fect­ed by the lat­est changes. Anne-Grethe Mortensen, head of glob­al mar­ket­ing, is leav­ing the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.